Radiological failure · Children with extensive decay involving the dental pulp in primary teeth
Low-level laser therapy (LLLT) + calcium hydroxide showed no clear difference in radiological failure compared with calcium hydroxide (CH); GRADE not reported.
1 finding from 1 review
All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Recurrent venous thromboembolism (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
1 finding from 1 review
Recurrent venous thromboembolism · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in major bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).
1 finding from 1 review
Thrombocytopenia (main analysis‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Clinical failure · Children with extensive decay involving the dental pulp in primary teeth
1 finding from 1 review
Resolution of daytime urinary incontinence · children aged 5 to 16 years with daytime urinary incontinence
Voiding education with uroflow feedback and urotherapy showed no clear difference in resolution of daytime urinary incontinence at 6 to 12 months after 6… compared with urotherapy alone (low certainty).
1 finding from 1 review
Frequency of incontinence episodes · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Objective measurement of volume of incontinent episodes · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life measurements · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · children aged 5 to 16 years with daytime urinary incontinence
1 finding from 1 review
Time to occurrence of new ulcer · s
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants developing a new ulcer · s
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
MWD ‐ change from baseline · people with symptomatic peripheral arterial disease§
1 finding from 1 review
Change from baseline in 6MWT (metres) · people with symptomatic peripheral arterial disease§
1 finding from 1 review
PFWD (change in metres) (4–40 weeks' · people with symptomatic peripheral arterial disease§
1 finding from 1 review